Antiviral pathways were elevated early in COVID-19 patients, highlighting the importance of early antiviral therapies for efficacy, while inhibition of IL-6 related mechanisms and other immunomodulatory therapies should be considered for both severe sepsis and severe COVID-19, since both diseases have similar underlying immune dysfunction, particularly later in disease. The gene discussed is IL6; the disease is COVID-19.